Neuraxpharm
Neuraxpharm is a European leader in pharmaceuticals for disorders affecting the central nervous system (CNS).
Last updated September 2, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Neuraxpharm is a European pharmaceutical company specialized in the treatment of central nervous system (CNS) disorders. It has been a specialist in this field since 1985 and its portfolio includes more than 130 molecules and 50 brands, addressing a full spectrum of psychiatric and neurological disorders. The company develops and commercializes originator brands, biologic drugs, value-added medicines, generics, medical cannabis and consumer healthcare products.
History
Neuraxpharm has been a specialist in the field of central nervous system (CNS) disorders since 1985, with 40 years of experience. It is a European leader in pharmaceuticals for CNS disorders.
Recent events
Reported
Neuraxpharm announces acquisition of Buccolam rights[5]
Neuraxpharm announced an agreement to acquire the global rights to Buccolam from Takeda. The transaction was expected to close by the end of 2020, subject to customary legal and regulatory closing conditions; completion was not reported.
Reported
Neuraxpharm announces acquisition of S.T.U. GmbH[6]
Neuraxpharm announced its acquisition of S.T.U. GmbH, a Switzerland-based developer and distributor of cannabidiol consumer products. The transaction terms were not disclosed.
Sources6 sources
Cite this profile: Cite the canonical profile. /brand-wiki/neuraxpharm · Editorial policy · How profiles are compiled